These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20336715)

  • 1. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
    Levast M; Larrat S; Thelu MA; Nicod S; Plages A; Cheveau A; Zarski JP; Seigneurin JM; Morand P; Leroy V
    J Med Virol; 2010 May; 82(5):747-54. PubMed ID: 20336715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
    Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
    J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.
    Emara MH; El-Gammal NE; Mohamed LA; Bahgat MM
    Virol J; 2010 Nov; 7():324. PubMed ID: 21083926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
    Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
    N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
    Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
    Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of previous HBV infection on the course of chronic hepatitis C.
    De Maria N; Colantoni A; Friedlander L; Leandro G; Idilman R; Harig J; Van Thiel DH
    Am J Gastroenterol; 2000 Dec; 95(12):3529-36. PubMed ID: 11151889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
    Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
    J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of occult HBV infection in patients with chronic hepatitis C.
    Anwar W; Sarwar M; Hussain AB; Tariq WU; Saif M
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):192-5. PubMed ID: 16542598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver specimens and in serum samples.
    Fabris P; Biasin MR; Giordani MT; Berardo L; Menini V; Carlotto A; Miotti MG; Manfrin V; Baldo V; Nebbia G; Infantolino D
    Curr HIV Res; 2008 Mar; 6(2):173-9. PubMed ID: 18336266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
    Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
    Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?
    Rodríguez-Torres M; Gonzalez-Garcia J; Bräu N; Solá R; Moreno S; Rockstroh J; Smaill F; Mendes-Correa MC; DePamphilis J; Torriani FJ;
    J Med Virol; 2007 Jun; 79(6):694-700. PubMed ID: 17457912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].
    Zhang RF; Liu L; Zheng YF; Shen YZ; Chen J; Gu SM; Wang JR; Lu HZ
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):189-91. PubMed ID: 23967739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
    Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.
    Cardoso C; Alves AL; Augusto F; Freire R; Quintana C; Gonçalves M; Oliveira AP
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):142-6. PubMed ID: 23044809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.